Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering.
A protein that breast, lung and other cancers use to promote their spread—or metastasis—to the brain, has been identified by a team led by Weill Cornell Medicine and New York-Presbyterian investigators. The protein, CEMIP, will now be a focus of efforts to predict, prevent and treat brain metastases, which are a frequent cause of cancer deaths.
Weill Cornell Medicine has been awarded a prestigious grant from the National Institutes of Health to establish an Autoimmunity Center of Excellence dedicated to understanding the mechanisms that contribute to autoimmune diseases in children.Weill Cornell Medicine has been awarded a prestigious grant from the National Institutes of Health to establish an Autoimmunity Center of Excellence dedicated to understanding the mechanisms that contribute to autoimmune diseases in children.
Weill Cornell Medicine investigators Dr. David Lyden and Dr. Ari Melnick have been awarded Outstanding Investigator Awards from the National Cancer Institute.
A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body’s intercellular delivery service to spread to new locations in the body.
On a Tuesday in early June, just days before summer break, dozens of third-year medical students gathered in the Belfer Research Building to present findings from independent research projects they’d been working on since February.
Researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have received two grants from the Sohn Conference Foundation to advance their investigation into how cancer spreads in children.
